Researchers Database

morishita yoshiyuki

    ComprehensiveMedicine1 Professor
Last Updated :2021/10/19

Researcher Information


J-Global ID

Research Interests

  • 遺伝子治療   腎線維化   ドラッグ・デリバリ-   

Research Areas

  • Life sciences / Nephrology
  • Life sciences / Pharmaceuticals - analytical and physicochemistry

Academic & Professional Experience

  • 2013  Jichi Medical UniversitySchool of Medicine講師


  • Ito Chiharu, Ogura Manabu, Morishita Yoshiyuki, Takeshima Eri, Miki Atsushi, Takahashi Hideaki, Akimoto Tetsu, Kusano Eiji  Nihon Toseki Igakkai Zasshi  46-  (6)  561  -569  2013  [Not refereed][Not invited]
    The incidence of recurrent or bilateral chronic subdural hematoma has been shown to be high in hemodialysis patients. We report a hemodialysis patient who underwent emergency burr hole drainage for repeated chronic subdural hematoma a total of four times, and was subsequently diagnosed with hypofibrinogenemia. He started hemodialysis due to chronic renal damage with obstructive nephropathy in 2002. Prolonged PT-INR, but not APTT was noted in 2005 when compression hip screw fixation was performed for a left femur neck fracture. He had never presented with a major bleeding event before the onset of subdural hematoma. In January 2012, he exhibited bilateral subacute subdural hematoma, which was followed by the first burr hole drainage. Preoperative blood analysis at the third burr hole drainage revealed that his plasma fibrinogen level was not detected by the Clauss method. Immuno-quantitative analysis for plasma fibrinogen determined its level as 106 mg/dL. A mixing test for prolonged PT, in which the patient's plasma was mixed with normal pooled plasma, showed a factor deficient pattern. The anti-fibrinogen antibody was negative and his past thromboembolic event was denied. A fibrinogen preparation was administrated to prevent the augmentation of postoperative subdural hemorrhage. Since <I>in vivo</I> recovery with the immuno-quantitative method for his plasma fibrinogen level was 69%, the presence of a fibrinogen inhibitor was ruled out. Although the detailed relationship between subdural hematoma and his coagulation abnormality was obscure, the occurrence of subdural hematoma and the possibility of abnormal fibrinogen levels should be considered.
  • MASUDA Takahiro, AMEMIYA Morimasa, OTOMO Takashi, MORISHITA Yoshiyuki, TSURUOKA Hidekazu, MUTO Shigeaki, NAGAE Genta, INAMORI Hideaki, ISODA Norio, IDO Kenichi, SUGANO Kentaro, ASANO Yasushi, KUSANO Eiji  日本透析医学会雑誌 = Journal of Japanese Society for Dialysis Therapy  37-  (9)  1809  -1813  2004/09  [Not refereed][Not invited]
  • Yoshiyuki Morishita, Eiji Kusano, Tetsuo Umino, Jun Nemoto, Kaichirou Tanba, Yasuhiro Ando, Shigeaki Muto, Yasushi Asano  Japanese Journal of Nephrology  46-  (2)  59  -65  2004  [Not refereed][Not invited]
    Proteinuria is quantified for diagnostic and prognostic purposes and to assess responses to therapy. Methods used to assess urinary protein include 24-hour urine collection (24-Up) and determination of the ratio of protein to creatinine concentration (Up/Ucr) in simple voided urine samples (Up/Ucr quantitative method). However, these methods are costly and time consuming. The Multistix PRO 11 (Bayer Medical Co., Ltd., Tokyo, Japan) is a new urine dipstick that allows rapid measurement of Up/Ucr. Results obtained with the Multistix PRO 11 coincided well with those obtained with the 24-Up method (κ = 0.68) and the Up/Ucr quantitative method (κ = 0.75). However, Multistix PRO 11 did not accurately measure moderate to severe proteinuria (≧500 mg/g. Cr). Our findings suggest that Multistix PRO 11 is useful for the screening, assessment, and follow-up of mild proteinuria.

Copyright © MEDIA FUSION Co.,Ltd. All rights reserved.